Krystal Biotech, Inc. $KRYS Shares Sold by US Bancorp DE

US Bancorp DE trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 37.8% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 639 shares of the company’s stock after selling 388 shares during the period. US Bancorp DE’s holdings in Krystal Biotech were worth $115,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. LPL Financial LLC lifted its holdings in Krystal Biotech by 156.8% in the fourth quarter. LPL Financial LLC now owns 2,946 shares of the company’s stock worth $462,000 after acquiring an additional 1,799 shares during the last quarter. Wells Fargo & Company MN grew its position in Krystal Biotech by 21.3% in the fourth quarter. Wells Fargo & Company MN now owns 16,928 shares of the company’s stock worth $2,652,000 after buying an additional 2,972 shares during the last quarter. Envestnet Asset Management Inc. grew its position in Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock worth $1,822,000 after buying an additional 121 shares during the last quarter. Bank of Montreal Can grew its position in Krystal Biotech by 5.7% during the 4th quarter. Bank of Montreal Can now owns 3,325 shares of the company’s stock worth $521,000 after purchasing an additional 179 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Krystal Biotech during the 4th quarter worth approximately $15,989,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on KRYS shares. Bank of America decreased their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Guggenheim cut their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Chardan Capital restated a “buy” rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Tuesday, August 5th. HC Wainwright reissued a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Friday, July 25th. Finally, Citigroup restated a “neutral” rating and issued a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and a consensus target price of $210.75.

Insider Activity

In other news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider owned 1,508,056 shares of the company’s stock, valued at $226,208,400. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 49,800 shares of company stock worth $7,487,943 over the last ninety days. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $150.27 on Monday. The company’s 50 day simple moving average is $143.40 and its 200 day simple moving average is $155.00. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $207.84. The firm has a market capitalization of $4.35 billion, a P/E ratio of 30.54 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).